Skip to main content
Cora Sternberg, MD, Oncology, New York, NY, New York-Presbyterian Hospital

CoraNanetteSternbergMD

Oncology New York, NY

Physician

Overview of Dr. Sternberg

Dr. Cora Sternberg is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, New York-Presbyterian Hospital, New York-Presbyterian Hospital, and NewYork-Presbyterian/Columbia University Irving Medical Center. She received her medical degree from Perelman School of Medicine at the University of Pennsylvania and has been in practice 39 years. She is one of 368 doctors at New York-Presbyterian Hospital and one of 115 doctors at NewYork-Presbyterian/Columbia University Irving Medical Center who specialize in Oncology. She also speaks multiple languages, including Italian. She has more than 100 publications and over 500 citings.

Education & Training

  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemResidency, Internal Medicine, 1978 - 1981
  • Perelman School of Medicine at the University of Pennsylvania
    Perelman School of Medicine at the University of PennsylvaniaClass of 1978

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1979 - Present
  • NY State Medical License
    NY State Medical License 1978 - 2025
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma  
    Cora N Sternberg, Jeanny B Aragon-Ching, Daniel P Petrylak, Petros Grivas, The New England Journal of Medicine

Other

Press Mentions

  • ASCO GU 2021: PI3K/AKT Pathway Biomarkers Analysis from the Phase III IPATential150 Trial of Ipatasertib plus Abiraterone in Metastatic Castration-Resistant Prostate Cancer
    ASCO GU 2021: PI3K/AKT Pathway Biomarkers Analysis from the Phase III IPATential150 Trial of Ipatasertib plus Abiraterone in Metastatic Castration-Resistant Prostate CancerFebruary 12th, 2021
  • Current Treatment Approaches in Advanced Urothelial Carcinoma - Shilpa Gupta
    Current Treatment Approaches in Advanced Urothelial Carcinoma - Shilpa GuptaSeptember 8th, 2020
  • Abiraterone or Docetaxel: Which Is Optimal for Hormone-Sensitive High-Risk Prostate Cancer?
    Abiraterone or Docetaxel: Which Is Optimal for Hormone-Sensitive High-Risk Prostate Cancer?October 25th, 2017
  • Join now to see all

Other Languages

  • Italian

Hospital Affiliations